Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A medical device comprising a site-specific delivery device for the controlled release of at least one peroxisome proliferator-activated receptor gamma (PPARγ) agonist.

Claim 2 (previously presented): The medical device according to claim 1 wherein said PPARγ agonist is rosiglitazone.

Claim 3 (canceled)

Claim 4 (canceled)

Claim 5 (previously presented): The medical device according to any of claims 1 or 2 or 4 wherein said medical device is a stent.

Claim 6 (original): The medical device according to claim 5 wherein said stent is a vascular stent or biliary stent.

Claim 7 (previously presented): The medical device according to claim 6 wherein said vascular stent is provided with a coating comprising rosiglitazone.

Claim 8 (canceled)

Claim 9 (currently amended): The medical device according to claim [8] 1 wherein said coating further contains a biocompatible polymer selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.

Claim 10 (canceled)

Claim 11 (previously presented): A medical device comprising a stent having a coating comprising rosiglitazone; and

a polymer selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.

Claims 12-20 (canceled)

Claim 21 (previously presented): A medical device comprising a stent having a coating comprising rosiglitazone; and

at least one additional therapeutic agent selected from the group consisting of antiplatelet agents, antimigratory agent, antifibrotic agents, antiproliferatives, antiinflammatories and combinations thereof providing that said additional therapeutic agent is not a PPARγ agonist.

Claim 22 (original): The medical device according to claim 21 wherein said at least one additional therapeutic agent is selected from the group consisting of antisense oligonucleotides, rapamycin, analogues of rapamycin, exochelin, n-acetyl cysteine inhibitors, chaperone inhibitors and combinations thereof.

Claim 23 (original): The medical device according to claim 22 wherein said antisense oligonucleotide is an anti-c-myc oligonucleotide.

Claim 24 (original): The medical device according to claim 22 wherein said chaperone inhibitor is geldanamycin.

Claim 25 (original): The medical device according to claim 22 wherein said rapamycin derivative is 40-0-(2-hydroxyethyl)-rapamycin.

Claim 26 (canceled)